Stoke Therapeutics, Inc. (STOK) Stock

Understand Stoke Therapeutics, Inc.: how it makes money

Stoke Therapeutics develops antisense oligonucleotide, or ASO, medicines for severe genetic diseases, using its Targeted Augmentation of Nuclear Gene Output approach to design therapies, with lead programs including STK-001 in phase I/IIa for Dravet syndrome and STK-002 in preclinical for autosomal dominant optic atrophy.

As an early-stage biopharmaceutical company, its future profit potential is structurally tied to whether its clinical programs produce convincing, durable patient benefit and acceptable safety, which can then enable later-stage development and commercialization, since current operations are largely R&D and trial activity rather than selling finished products.

Business quality (Weak): Clear program focus (STK-001 and STK-002), but there are no reportable business segments and profitability is currently deeply negative, so investors largely need to underwrite progress and retention signals from ongoing studies and future trial milestones.

Bull case

• Open-label retention signals for Zoriba-Nursen: In the open-label extension, the Open-Label Extension Patient Remaining Rate (Four-Year Data Cutoff) is 77.0 percent and the Open-Label Extension Patient Continuation Rate (Zoriba-Nursen) is 93.0 percent.
• Observed biomarker-related signal and safety data disclosures: Cerebrospinal Fluid Protein Elevation Incidence is reported at approximately 94.0 percent, and Treatment-Emergent Serious Adverse Event Incidence is 22.0 percent (Phase 1 and 2A) and 29.0 percent in the open-label extension.

Bear case

• No current product revenue and large operating losses: For the latest reported period, revenue is shown as 0.0B and operating margin is -857.6 percent, indicating profitability depends on future clinical and commercialization outcomes.
• Safety variability across study phases: Treatment-Emergent Serious Adverse Event Incidence is 22.0 percent (Phase 1 and 2A) and 29.0 percent in the open-label extension, which highlights the need to monitor safety as programs progress.
• Stage risk across the pipeline: STK-001 is in phase I/IIa and STK-002 is in preclinical, so both programs face early-development execution and translation risk before any late-stage evidence.

Related Companies (Pharmaceutical Products; 8 comparable drugmakers)

• Maravai LifeSciences Holdings, Inc. (MRVI)
• Rhythm Pharmaceuticals, Inc. (RYTM)
• Cryoport, Inc. (CYRX)
• Phathom Pharmaceuticals, Inc. (PHAT)
• Syndax Pharmaceuticals, Inc. (SNDX)
• Vanda Pharmaceuticals Inc. (VNDA)
• IDEAYA Biosciences, Inc. (IDYA)
• Heron Therapeutics, Inc. (HRTX)